Mayne Pharma
Australian specialty pharma making women's health and dermatology prescription drugs.
On the record
Checkpoint: FY26 full-year earnings report, will show whether GAAP losses continue and how DistributeRx is scaling
The call
Mayne Pharma is growing revenue and margins on real patents, but a generics fight over IMVEXXY, a collapsed buyout with live litigation, and ongoing net losses leave the picture unsettled.
Mayne Pharma makes branded prescription drugs, mainly for women's health, and sells them directly to patients through a new program called DistributeRx to skip middlemen who control drug pricing. The company has real FDA-approved medicines with patent protection, but Sun Pharma and Teva are filing to sell cheaper copies of its biggest product, IMVEXXY, and the company is fighting a lawsuit over a failed acquisition that could cost it money. What matters most is whether DistributeRx grows fast enough to replace lost sales when patents expire, whether Mayne wins its legal fights with Sun Pharma and Teva, and whether the Cosette lawsuit gets resolved without huge damages.
Why
01
AI pressure: None apparent. AI drug discovery tools don't touch Mayne's business, it makes and sells already-approved generics and branded drugs. Could AI do the core job? Unlikely.
02
Bigger players: Sun Pharma and Teva Pharmaceuticals (ANDA filers against IMVEXXY). Sun Pharma and Teva have filed to make generic versions of IMVEXXY, Mayne's flagship women's health drug, court fight is ongoing. Could a giant copy it? Probably.
03
What protects it. Orange Book patents on IMVEXXY plus FDA exclusivity, and a new direct-to-patient channel (DistributeRx) that skips pharmacy middlemen.
What would change this call
Ruling or settlement in Sun Pharma/Teva ANDA litigation over IMVEXXY patents. Shows whether Mayne keeps IMVEXXY exclusivity or faces generic revenue loss.
Cosette Pharmaceuticals appeal ruling following May 2026 briefs. Shows whether Mayne faces a damages payout from the failed acquisition.
Dermatology segment revenue trend in FY26 results (was -12% in FY25). Shows whether Galderma and other derm rivals continue taking share.
Cosette Pharmaceuticals appeal ruling following May 2026 briefs. Shows whether Mayne faces a damages payout from the failed acquisition.
Dermatology segment revenue trend in FY26 results (was -12% in FY25). Shows whether Galderma and other derm rivals continue taking share.
Key numbers
- FY25 revenue A$408.1m, up 5.1% year over year
- FY25 underlying EBITDA up 105% to A$47.0m
- FY25 net loss to shareholders A$93.8m
Named risks
- Generic ANDA entry from Sun Pharma/Teva could erode IMVEXXY, a core flagship women's health product.
- Cosette appeal of MAC ruling could lead to damages claims against Mayne.
- Company remains net-loss making (-A$93.8m FY25 NPAT) despite EBITDA gains.
- Two leadership transitions (CEO Feb 2026, CFO Aug 2026) within six months create execution risk.
- Dermatology segment revenue declined 12% in FY25, showing erosion in a core franchise.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Sun Pharma and Teva Pharmaceuticals | gaining on | Filed ANDAs contesting 20 patents around IMVEXXY, active litigation as of 15 June 2026 |
| Cosette Pharmaceuticals | contesting | Appealing NSW Supreme Court MAC ruling and flagging damages claims, submissions filed 20 May 2026 |
| Galderma | contesting | Authorized generic gORACEA competes against Mayne's ORACEA generics per 2023 disclosure |
Questions people ask
- Is Mayne Pharma profitable in 2026?
- No. Mayne Pharma reported a FY25 net loss attributable to shareholders of A$93.8m (year ended 30 June 2025), despite underlying EBITDA rising 105% to A$47.0m. TTM net income was still -A$82.2m as of mid-2026, per FT market data dated 16 July 2026.
- Is Mayne Pharma still being acquired by Cosette Pharmaceuticals?
- No. The Cosette acquisition deal (signed 20 February 2025 at A$7.40/share, roughly A$672m total) collapsed when both parties served termination notices on 9-11 December 2025 after an NSW Supreme Court MAC dispute. Cosette is now appealing that ruling as of May 2026 and has flagged possible damages claims.
- Who is Mayne Pharma's biggest competitive threat?
- Sun Pharma and Teva Pharmaceuticals, which have filed generic ANDAs against Mayne's flagship women's health drug IMVEXXY, contesting 20 asserted patents as of a 15 June 2026 litigation report. A loss would open IMVEXXY, part of a US$69.1m FY25 product group, to generic competition.
- Could AI replace Mayne Pharma's business?
- Unlikely in its core operations. Mayne's moat rests on FDA-approved manufacturing sites, Orange Book patents, and physical distribution infrastructure like its DistributeRx pharmacy network launched 10 March 2026, none of which frontier AI models can replicate; back-office and marketing tasks are more exposed.
- What is Mayne Pharma's DistributeRx and why does it matter?
- DistributeRx is Mayne Pharma's direct-to-patient distribution platform launched 10 March 2026, bypassing PBMs and wholesalers via cash-pay pricing and its own pharmacies. Non-wholesale channel volume hit 59% of group volume in 1H FY26, with cash-pay prescriptions growing at an 83% CAGR since FY23.
- Who owns Mayne Pharma Group?
- Mayne Pharma is an independent, publicly listed company on the ASX (ticker MYX) with no parent company, after its planned acquisition by Cosette Pharmaceuticals fell through in December 2025. Its market capitalization was roughly A$220m as of 25 July 2026.
Timeline
- 2026-07-17New CFO Griffin D. Buchanan appointed, effective 1 August 2026
- 2026-05-20Cosette files written submissions in reply for NSW Court of Appeal
- 2026-03-10DistributeRx direct-to-patient distribution platform launched
- 2026-02-20CEO Shawn O'Brien steps down; CFO Aaron Gray becomes CEO
- 2025-12-11Cosette and Mayne both serve termination notices, deal collapses
- 2025-11-12FDA announces intent to remove black-box warnings from HRT products
- 2025-02-20Cosette signs Scheme Implementation Deed to acquire Mayne at A$7.40/share
- 2007-06-29Mayne Pharma lists on the ASX
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- MAYNE PHARMA REPORTS FY25 FINANCIAL RESULTS (2025-08-29)
- Full Year Statutory Accounts
- Mayne Pharma Group Ltd, MYX:ASX profile (2026-07-16)
- DRAFT ASX announcement
- DRAFT ASX announcement (3Q FY26)
- Cosette Pharmaceuticals Announces Acquisition of Mayne Pharma (2025-02-20)
- Termination of Proposed Acquisition of Mayne Pharma (2025-12-11)
- Written Submissions in Reply (2026-05-20)
- gurufocus.com (2026-07-25)
- DRAFT ASX announcement (DistributeRx launch)
- Mayne Pharma Group (MYX) Investor update Summary
- Annual Report 2025